Abstract: During the past few years, European consensus on grading bone marrow fibrosis, the Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis(PMF) and response criteria for PMF were developed, and some new drugs, such as the immunomodulator drugs (IMiDs) and JAK2 inhibitor are available for PMF. The recent advances were summarized and future issues were discussed.